Bomb Report – Lifestyle
Author:
Aura Biosciences, Inc.
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
May 4, 2026
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 4, 2026
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
May 4, 2026
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
March 30, 2026
Aura Biosciences to Participate in Upcoming Investor Conferences
March 5, 2026